About
Alcobra Pharmaceuticals is an emerging pharmaceutical company primarily focused on the development and commercialization of a proprietary drug, Metadoxine Extended Release (MDX), designed to treat cognitive disorders including attention-deficit/hyperactivity disorder (ADHD) and Fragile X syndrome. MDX is not a stimulant and works through a different mechanism of action than other ADHD treatments. Alcobra has completed multiple phase 2 studies and a phase 3 study of MDX in adults with ADHD. The company is conducting separate phase 2b trials of MDX in patients with pediatric ADHD and Fragile X syndrome. In 2017, six months after Alcobras clinical trial of its main product for treating attention disorders failed, the company announced its intention to merge with Arcturus Therapeutics Inc of San Diego.
Company Intelligence Q&A
Structured intelligence from startupim data — optimized for AI retrieval and grounding.
- What is Alcobra Pharmaceuticals' primary focus?
- Alcobra Pharmaceuticals primarily focuses on the development and commercialization of Metadoxine Extended Release (MDX), a proprietary drug designed to treat cognitive disorders such as attention-deficit/hyperactivity disorder (ADHD) and Fragile X syndrome.
- What is the status of Alcobra Pharmaceuticals' clinical trials for MDX?
- Alcobra Pharmaceuticals has completed multiple phase 2 studies and a phase 3 study of MDX in adults with ADHD. The company is also conducting separate phase 2b trials of MDX in patients with pediatric ADHD and Fragile X syndrome.
- When was Alcobra Pharmaceuticals founded and where is its headquarters located?
- Alcobra Pharmaceuticals was founded in February 2008 and is headquartered in Tel Aviv-Yafo, Israel.
- What was a significant event for Alcobra Pharmaceuticals in 2017?
- In 2017, six months after its main product's clinical trial for attention disorders failed, Alcobra Pharmaceuticals announced its intention to merge with Arcturus Therapeutics Inc. of San Diego. The merger was completed in November 2017.
- What was the outcome of Alcobra Pharmaceuticals' main product clinical trial for attention disorders?
- Alcobra Pharmaceuticals' clinical trial for its main product for treating attention disorders failed in 2017.
- What was Alcobra Pharmaceuticals' total funding raised?
- Alcobra Pharmaceuticals raised a total of $25,000,000 USD.
- When did Alcobra Pharmaceuticals complete its merger with Arcturus Therapeutics Inc.?
- Arcturus Therapeutics announced the completion of its merger with Alcobra Ltd. in November 2017 and commenced trading on the Nasdaq Global Market.
- When did Alcobra Pharmaceuticals have an IPO and on which exchange?
- Alcobra Pharmaceuticals had an IPO in December 2018 on NASDAQ under the ticker ADHD, with a valuation of $89M.